NCT03615183View on ClinicalTrials.gov

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

September 26, 2019

Study Completion Date

September 26, 2019

Conditions
Human Immunodeficiency VirusAIDS Virus
Interventions
DRUG

MK-8527

Single oral capsule

Trial Locations (1)

021105

Matei Bals Infectious Diseases Institute ( Site 0001), Bucharest

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03615183 - A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) | Biotech Hunter | Biotech Hunter